The Claim
Among persons living with HIV, initiation of high-intensity statins occurs in only 9.8% of cases, and after multivariable adjustment, there is no statistically significant association between the intensity of statin therapy and the likelihood of achieving a ≥30% reduction in LDL cholesterol, suggesting that current prescribing practices may not maximize lipid-lowering efficacy in this population.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
Only about 1 in 10 people with HIV are given the strongest cholesterol-lowering pills, and even when they are, those stronger pills don’t seem to work any better at lowering bad cholesterol than weaker ones—so doctors might not be prescribing them in the best way.
See the scientific wording
Among persons living with HIV, initiation of high-intensity statins is rare (9.8%), and no significant association exists between statin intensity and achieving ≥30% LDL-C reduction after multivariable adjustment, suggesting current prescribing patterns may not optimize lipid-lowering efficacy.
What the research says
1 studyThe study found that people with HIV rarely get the strongest statin pills, and even when they do, it doesn’t always lower their bad cholesterol enough — so doctors aren’t using the best treatments as much as they should.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.